Search
KB002
go.drugbank.com/drugs/DB05194ExperimentalKB002 is an engineered human IgG1k antibody engineered human. It is developed for the treatment of autoimmune diseases, initially rheumatoid arthritis.
Rufinamide
go.drugbank.com/drugs/DB06201ApprovedClinical trials suggest its efficacy in the treatment of partial seizures. … Rufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of childhood epilepsy.
Nisin Z
go.drugbank.com/drugs/DB19122InvestigationalNisin Z is under investigation in clinical trial NCT06097468 (Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC)).
Categories: Compounds used in a research, industrial, or household settingCacodylic acid
go.drugbank.com/drugs/DB02994ExperimentalCategories: Compounds used in a research, industrial, or household settingPradefovir mesylate
go.drugbank.com/drugs/DB05478Investigational[Adefovir] (Hepsera) is an acyclic phosphonate analogue of adenine that is used to treat hepatitis B virus. … The novel prodrug is highly stable in both plasma and tissues and demonstrated potent preclinical and clinical anti-HBV activity.
Cilomilast
go.drugbank.com/drugs/DB03849InvestigationalFollowing four clinical trials, the drug proved to be effective in treating COPD, however it has never been marketed due to a poor side effect profile.
Tacrine
go.drugbank.com/drugs/DB00382ApprovedWithdrawnA centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous
Heptaminol
go.drugbank.com/drugs/DB13574InvestigationalCategories: Vasodilators Used in Cardiac DiseasesFerric pyrophosphate citrate
go.drugbank.com/drugs/DB13995Approved[A31979] FPC is categorized in Japan as a second class OTC drug. … Free iron presents several side effects as it can catalyze free radical formation and lipid peroxidation as well as the presence of interactions of iron in plasma.
Ertiprotafib
go.drugbank.com/drugs/DB06521ExperimentalIn insulin-resistant rodent models, ertiprotafib and a close analog lowered both fasting blood glucose and insulin levels and improved glycemic excursion during an oral glucose tolerance test.